Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug
12:49pm, Thursday, 02'nd Jun 2022
The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
07:50am, Thursday, 02'nd Jun 2022
Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collabora
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
06:39pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
06:22pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
03:48pm, Wednesday, 01'st Jun 2022
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II
12:47pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of ca
FDA gives Sanofi's experimental hemophilia A drug a Breakthrough Therapy designation
08:40am, Wednesday, 01'st Jun 2022
Sanofi SNY, -3.45% SAN, +1.17% said Wednesday that the Food and Drug Administration granted a Breakthrough Therapy designation to the hemophilia A treatment it's developing with Swedish Orphan Biovitr
Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag
02:16pm, Tuesday, 31'st May 2022 Zacks Investment Research
The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
12:04pm, Tuesday, 31'st May 2022
The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) f
Sanofi Ordered to Delay Trial for OTC Cialis. The Stock Falls.
11:03am, Tuesday, 31'st May 2022
The setback could raise fears about the future of the French company's consumer division, which is also seeing delays in an OTC version of Tamiflu.
3 Unstoppable Stocks That Are Higher Than Before the Market Correction
03:45pm, Friday, 27'th May 2022 The Motley Fool
Market downturns don't affect stocks equally.
Sanofi: Reliance On One Drug Strategy May Bite
02:29am, Friday, 27'th May 2022
Sanofi's strong reliance on a single product Dupixent poses risks as competition in atopic dermatitis segment increases. It struggled to show any superiority in COVID-19 vaccine development and is sti
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
11:42am, Thursday, 26'th May 2022 The Motley Fool
New treatments will step in to replace blockbuster eye medication EYLEA.
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
02:06pm, Wednesday, 25'th May 2022 Zacks Investment Research
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
05:09am, Wednesday, 25'th May 2022 Zacks Investment Research
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
